Bruker Corp. (BRKR) financials: revenue, earnings and cash flow
Fiscal 2016–2025 + TTM · from SEC filings · data as of November 13, 2026
Summary
Bruker’s revenue went from $1.6B in fiscal 2016 to $3.4B in fiscal 2025, growth of about 8.8% a year.
Net income in fiscal 2025 was -$9M, a net margin of -0.3%; the best year in this period was 2023 with $427M.
Over the twelve months to September 30, 2026, revenue was $3.5B and net income -$167M.
Free cash flow was $43M in fiscal 2025 and positive in 10 of the 10 years shown.
The diluted share count fell 6% over the period (buybacks).
Revenue, profit and cash flow by year
Income statement
| Fiscal year | TTM | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | $3.5B | $3.4B | $3.4B | $3.0B | $2.5B | $2.4B | $2.0B | $2.1B | $1.9B | $1.8B | $1.6B |
| Gross profit | $1.7B | $1.6B | $1.6B | $1.5B | $1.3B | $1.2B | $940M | $995M | $900M | $816M | $745M |
| Operating income | -$70M | $68M | $253M | $437M | $433M | $413M | $248M | $301M | $262M | $220M | $182M |
| Net income | -$167M | -$9M | $113M | $427M | $297M | $277M | $158M | $197M | $180M | $79M | $154M |
| EPS (diluted) | $-1.10 | $-0.15 | $0.76 | $2.90 | $0.00 | $0.00 | $0.00 | $0.00 | $1.14 | $0.49 | $0.95 |
| R&D | $387M | $395M | $376M | $295M | $236M | $221M | $198M | $188M | $173M | $162M | $148M |
| Revenue growth | — | +2.1% | +13.6% | +17.1% | +4.7% | +21.7% | −4.1% | +9.3% | +7.3% | +9.6% | −0.8% |
Cash flow
| Fiscal year | TTM | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Operating cash flow | $342M | $134M | $251M | $350M | $274M | $282M | $332M | $213M | $240M | $154M | $131M |
| Capital spending | -$97M | -$91M | -$115M | -$107M | -$129M | -$92M | -$97M | -$73M | -$49M | -$44M | -$37M |
| Free cash flow | $245M | $43M | $136M | $243M | $145M | $190M | $235M | $140M | $190M | $111M | $94M |
| Dividends paid | $30M | $23M | $30M | $29M | $30M | $24M | $25M | $25M | $25M | $25M | $26M |
| Buybacks | — | $10M | $0 | $152M | $263M | $153M | $123M | $142M | — | $152M | $160M |
| Stock-based pay | $24M | $20M | $25M | $31M | $28M | $17M | $16M | $10M | $11M | $11M | $9M |
Balance sheet
| Fiscal year | TTM | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Cash | — | $299M | $183M | $488M | $646M | $1.2B | $732M | $685M | $322M | $439M | $342M |
| Debt | — | $2.0B | $2.2B | $1.4B | $1.3B | $1.4B | $913M | $881M | $341M | $416M | $412M |
| Equity | — | $2.5B | $1.8B | $1.4B | $1.1B | $1.1B | $961M | $907M | $897M | $725M | $686M |
| Total assets | — | $6.2B | $5.8B | $4.2B | $3.6B | $3.6B | $3.0B | $2.8B | $2.1B | $1.9B | $1.8B |
| Shares (diluted) | 152M | 152M | 150M | 147M | 149M | 153M | 155M | 157M | 157M | 159M | 162M |
Margins and returns
| Fiscal year | TTM | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Gross margin | 47.7% | 45.9% | 49.0% | 51.0% | 51.6% | 50.0% | 47.3% | 48.0% | 47.5% | 46.2% | 46.2% |
| Operating margin | -2.0% | 2.0% | 7.5% | 14.7% | 17.1% | 17.1% | 12.5% | 14.5% | 13.8% | 12.4% | 11.3% |
| Net margin | -4.8% | -0.2% | 3.4% | 14.4% | 11.7% | 11.5% | 7.9% | 9.5% | 9.5% | 4.5% | 9.5% |
| FCF margin | 7.0% | 1.3% | 4.0% | 8.2% | 5.7% | 7.9% | 11.8% | 6.8% | 10.1% | 6.3% | 5.8% |
| ROIC | — | 1.2% | 3.5% | 12.4% | 13.0% | 12.0% | 9.5% | 11.9% | 15.7% | 15.2% | 14.4% |
| ROE | — | -0.4% | 6.3% | 31.0% | 26.6% | 25.9% | 16.4% | 21.8% | 20.0% | 10.8% | 22.4% |
Frequently asked questions
What is Bruker’s annual revenue?
$3.4B in fiscal 2025 and $3.5B over the twelve months to September 30, 2026.
How much profit does Bruker make?
Net income was -$9M in fiscal 2025 (net margin -0.3%).
Is Bruker’s revenue growing?
Yes: revenue rose 2.1% in fiscal 2025 compared with the year before.
From the company’s 10-K and 10-Q filings with the SEC; per-share figures adjusted for stock splits. Rebuilt daily. Not investment advice.